AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces
Unmet need in acute myeloid leukemia is very high, but that doesn't mean standards will be low for the many companies pursuing therapies in the space.
You may also be interested in...
This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.
Clinicians weigh in on updated data presented at ASH in frontline acute myeloid leukemia, but caution that it is difficult to compare across clinical trials.
Tibsovo is the second targeted therapy approved for a mutation-specific subset of relapsed/refractory AML patients. Agios discovered and jointly markets the first, Idhifa, with Celgene.